DVAX
Dynavax Technologies Corp
NASDAQ · Biotechnology
$15.50
+0.01 (+0.06%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 244.15M | 284.66M | 325.64M | 289.50M | 362.88M |
| Net Income | 24.05M | 25.23M | -79,304,400 | -60,500,728 | -70,252,711 |
| EPS | — | — | — | — | — |
| Profit Margin | 9.9% | 9.4% | -24.4% | -20.9% | -19.4% |
| Rev Growth | -14.2% | -14.2% | +24.6% | -5.1% | -3.4% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 248.24M | 248.24M | 358.40M | 426.75M | 382.87M |
| Total Equity | 661.80M | 661.80M | 1.03B | 934.57M | 930.66M |
| D/E Ratio | 0.38 | 0.38 | 0.35 | 0.46 | 0.41 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | 4.85M | 5.37M | -97,613,714 | -85,556,315 | -114,728,260 |
| Free Cash Flow | — | — | -64,985,684 | -57,246,430 | -70,359,269 |